Chemed Co. (NYSE:CHE – Get Free Report) CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $572.77, for a total transaction of $1,145,540.00. Following the completion of the sale, the chief executive officer now directly owns 101,735 shares of the company’s stock, valued at $58,270,755.95. This trade represents a 1.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Chemed Stock Down 0.4 %
Shares of CHE opened at $571.29 on Thursday. Chemed Co. has a 52-week low of $523.33 and a 52-week high of $654.62. The firm has a market cap of $8.60 billion, a price-to-earnings ratio of 28.87, a PEG ratio of 2.43 and a beta of 0.46. The business’s 50 day moving average is $578.86 and its two-hundred day moving average is $564.98.
Chemed (NYSE:CHE – Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $5.64 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.76 by ($0.12). The company had revenue of $606.18 million during the quarter, compared to analyst estimates of $612.22 million. Chemed had a net margin of 12.69% and a return on equity of 27.86%. The company’s revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the company earned $5.32 earnings per share. On average, equities analysts expect that Chemed Co. will post 21.43 earnings per share for the current fiscal year.
Chemed Dividend Announcement
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its position in shares of Chemed by 34.4% during the 2nd quarter. GAMMA Investing LLC now owns 86 shares of the company’s stock valued at $47,000 after acquiring an additional 22 shares in the last quarter. EP Wealth Advisors LLC increased its stake in Chemed by 1.9% during the third quarter. EP Wealth Advisors LLC now owns 1,354 shares of the company’s stock valued at $814,000 after purchasing an additional 25 shares during the last quarter. Ballentine Partners LLC raised its holdings in shares of Chemed by 4.1% during the third quarter. Ballentine Partners LLC now owns 655 shares of the company’s stock worth $394,000 after purchasing an additional 26 shares during the period. Everpar Advisors LLC lifted its position in shares of Chemed by 4.9% in the 2nd quarter. Everpar Advisors LLC now owns 580 shares of the company’s stock worth $315,000 after buying an additional 27 shares during the last quarter. Finally, Creative Planning boosted its holdings in shares of Chemed by 2.8% in the 2nd quarter. Creative Planning now owns 1,228 shares of the company’s stock valued at $667,000 after buying an additional 34 shares during the period. Institutional investors own 95.85% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on CHE. Royal Bank of Canada lowered their price target on shares of Chemed from $697.00 to $633.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. StockNews.com downgraded Chemed from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd.
Check Out Our Latest Stock Report on CHE
About Chemed
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
See Also
- Five stocks we like better than Chemed
- How to buy stock: A step-by-step guide for beginners
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.